

Pfizer

UK: +44 (0)207 989 0813 NA: +1 646 896 3065 AU +61 2 9280 0700 action@proactiveinvestors.com

10:40 09 May 2019

Pharma stocks head south as Trump forces them to display drug prices in TV ads

Pharma stocks around the world headed lower on Thursday after President Donald Trump warned drugmakers they will have to list the price of their drugs in television adverts.

Companies will have to include the price for any medication that costs more than US\$35 for a month's supply or the usual course of treatment.

"If drug companies are ashamed of those prices - lower them!" Trump tweeted on Wednesday afternoon.

Big announcement today: Drug companies have to come clean about their prices in TV ads. Historic transparency for American patients is here. If drug companies are ashamed of those prices—lower them!

— Donald J. Trump (@realDonaldTrump) May 8, 2019 Pfizer Inc (NYSE:PFE), AbbVie Inc (NYSE:ABBV) and Gilead Sciences Inc (NASDAQ:GILD) all dropped between 1.5-2% on the back of the news.

In the UK, shares in AstraZeneca PLC (LON:AZN) and GlaxoSmithKline PLC (LON:GSK) also fell.

Lowering drug prices has been a key focus for Trump and his administration, which last year set out their blueprint for bringing down prices of prescription drugs.

Two bills were passed by US politicians on Wednesday aimed at making cheaper generic drugs more available, with no votes against.

"Requiring the inclusion of drugs' list prices in TV ads is the single most significant step any administration has taken toward a simple commitment: American patients deserve to know the prices of the healthcare they receive," said health & human services secretary Alex Azar.

Price: 35.45

Market Cap: \$196.99 billion

1 Year Share Price Graph

45
40
35
30
25

October 2019 April 2020 October 202

Share Information

 Code:
 PFE

 Listing:
 NYSE

 52 week
 High
 Low

 40.93
 27.89

Sector: Pharma & Biotech
Website: www.pfizer.com

Company Synopsis:

Pfizer are committed to applying science and our global resources to improve health and wellbeing at every stage of life. They strive to provide access to clinically effective and affordable medicines and related healthcare services to the people who need them.

action@proactiveinvestors.com

Experts have warned that such adverts may scare patients away from drugs they could actually afford with their health insurance coverage.

Lobby groups for the pharma industry said the new rule raises First Amendment concerns, as well as challenges implementing it within 60 days.



Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.